Stada And Alvotech Eye Launch Date For Ustekinumab After EU Approval
As Stada Partners With Zuellig In The Philippines On Prescription And Consumer Range
Stada has revealed details of exactly when in 2024 it plans to launch its Alvotech-partnered Uzpruvo ustekinumab biosimilar to Stelara, having just been granted a pan-European marketing authorization. At the same time, the German firm has also struck a distribution deal for prescription and consumer healthcare products with Zuellig in the Philippines.
